Background: Despite advances in asthma treatment, severe asthma (SA) still results in high morbidity and use of health resources. Our hypothesis was that SA patients would achieve adequate control with a systematic protocol, including oral corticosteroids, budesonide/formoterol maintenance and reliever therapy and a multidisciplinary approach to improve adherence.

Methods: Non-controlled (NC) SA patients were enrolled to receive 2 weeks of oral corticosteroids and 12 weeks of formoterol + budesonide. Assessments included asthma control questionnaire (ACQ), asthma control test (ACT), daily symptom diary, lung function and health-related quality of life (HRQoL) questionnaires.

Results: Of 51 patients, 13 (25.5%) achieved control. NC patients had higher utilization of health resources and higher exacerbation rates. Both controlled (C) and NC patients had significantly reduced ACQ scores after oral corticosteroid treatment. After 12 weeks, C patients continued improving. NC patients did not have significant changes. A similar pattern was found regarding lung function, use of rescue medication, and days free of symptoms. After 2 weeks of oral corticosteroids, an increase occurred in those who achieved the ACQ cut off; however, 53.8% of C patients had an ACQ < 1.57 versus 21.1% of NC patients (p = 0.03). Both groups had low HRQoL at baseline with improvement after intervention.

Conclusions: Despite rigorous, optimized follow-up treatment, 75% of SA patients did not achieve adequate symptom control and presented with impaired quality of life. Conversely, application of a low-cost, easy to implement systematic protocol can prevent up to 25% of SA patients from up-titrating to new and complex therapies, thus reducing costs and morbidity.

Trial Registration: Retrospectively registered at ClinicalTrial.gov on 22 February 2010 ( NCT01089322 ).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112706PMC
http://dx.doi.org/10.1186/s12890-016-0314-1DOI Listing

Publication Analysis

Top Keywords

oral corticosteroids
12
patients
10
patients achieve
8
health resources
8
2 weeks oral
8
asthma control
8
lung function
8
asthma
6
control
5
severe asthmatic
4

Similar Publications

Effect of azithromycin combined with fluticasone propionate aerosol inhalation on immune function in children with chronic cough caused by Mycoplasma pneumoniae infection.

Eur J Pediatr

January 2025

Department of Pediatrics, Ganzhou People's Hospital, No. 16 Meiguan Avenue, Zhanggong District, Ganzhou, 341000, Jiangxi Province, China.

Unlabelled: This research aimed to describe the effect of azithromycin combined with fluticasone propionate aerosol inhalation on immune function in children with chronic cough caused by Mycoplasma pneumoniae (MP) infection. This study was a retrospective analysis in which 110 children with chronic cough caused by MP infection were divided into two groups based on different treatment methods: 58 cases in the control group treated with azithromycin dry suspension and 52 cases in the intervention group treated with azithromycin dry suspension and fluticasone propionate inhalation aerosol. Lung function, inflammatory factors, immune indicators, laboratory-related indicators, adverse reactions, and therapeutic effects were compared between the two groups.

View Article and Find Full Text PDF

Clinical outcomes in peripheral ulcerative keratitis.

Am J Ophthalmol

January 2025

the Wilmer Eye Institute, the Department of Ophthalmology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA; the Department of Epidemiology, the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address:

Purpose: To evaluate clinical and treatment outcomes in patients with peripheral ulcerative keratitis (PUK).

Design: Retrospective, case series SUBJECTS: Patients diagnosed with PUK at the Wilmer Eye Institute between January 2003 and October 2022.

Methods: Data collected included demographics, presence of systemic disease, disease laterality, duration of disease, PUK activity, presence of corneal perforation, and treatments.

View Article and Find Full Text PDF

Purpose: Oral corticosteroids (OCS) are recommended for the treatment of exacerbations in people with COPD; however, high cumulative lifetime doses (≥1000mg prednisolone-equivalent) are associated with adverse health effects. This issue is well defined in asthma but is less well understood in COPD. The aim of this study was to examine cumulative OCS dispensed to people with COPD over 12 months.

View Article and Find Full Text PDF

Background: Non-pharmaceutical interventions (NPIs) were widely used during the coronavirus disease 2019 (COVID-19) pandemic, however their impact on acute asthma exacerbations (AEs) is not well studied.

Methods: We had retrospectively collected patients with asthma AEs between 2019 and 2020 and retrieved data from the Chang Gung Research Database, including clinical manifestations, medications, pulmonary function, clinic and emergency department visits and hospitalizations.

Results: A total of 39,108 adult patients with asthma were enrolled, of whom 1502 were eligible for analysis.

View Article and Find Full Text PDF

Background: Sensory disorders of the inferior alveolar nerve, often arising from dental procedures, markedly impact the quality of life of patients. This article proposes a scoping review to analyze emerging trends in pharmacological treatment for these disorders, addressing scientific gaps and clinical practices.

Material And Methods: The review followed the PRISMA-ScR protocol, conducting data searches across various databases, including PubMed and Cochrane, until March 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!